Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Conditions

Subcategories:Axial SpondyloarthritisGout and Crystalline ArthritisGuidelinesMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

Vasculitis Guidelines in Focus, Part 3: EGPA

Michael Putman, MD  |  

In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).

Using Different Fibromyalgia Criteria Affects Prevalence Estimates

Deborah Levenson  |  

A recent paper illustrates how using different fibromyalgia criteria affects reports of its prevalence.1 Writing in Arthritis Care & Research, researchers found the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks–American Pain Society Pain Taxonomy (AAPT) criteria caused far more people to be categorized as having fibromyalgia than criteria put forth by…

COVID-19 & Pediatric Rheumatology

Elizabeth Sloan, MD  |  

PRSYM 2021—Although primary COVID-19 infection has the most significant complications in adult patients, pediatric rheumatologists have also seen significant changes in their practice over the past year. With the emergence of COVID-19, the rise of a mysterious post-COVID hyper­inflammatory syndrome, now known as multisystem inflammatory syndrome in children (MIS-C), was identified, and pediatric rheumatologists have…

Case Report: Sarcoidosis in Patient with History of IgG4-Related Disease

Veronica Matto, DO, Rajshri Shah, MD, Jie Ouyang, MD, PhD, Cory Perugino, DO, & Joseph J. LaConti, MD, PhD  |  

Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…

Case Report: A 5-Year-Old with an Ischemic Digit

Marta Michalska-Smith, MD, & Colleen K. Correll, MD, MPH  |  

Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…

Case Report: Drug-Induced Lupus

Haseeb Chaudhary, MD, Prem Parajuli, MD, & Devy Setyono, MD  |  

The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…

Case Report: Reactive Arthritis Following COVID-19

Samuel C. Purkey, DO, James Z. Drew, MD, & Marcum Collins, MD  |  

SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…

A Look Back at the ACR’s Strong Response to COVID-19

David R. Karp, MD, PhD  |  

We are now a year-and-a-half into the COVID‑19 pandemic, and rheuma­tologists and rheuma­tology professionals are still facing some of the same challenges that began in spring 2020, as well as new ones. Most recently, we learned that COVID‑19 vaccine efficacy is reduced in some patients on immunosuppressive therapies and the need for additional immunization is…